Work

141PD: Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials

Year: 2016

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/s1556-0864(16)30251-9

Authors: E. Felip, L. Crinò, D.-W. Kim, D.R. Spigel, M. Nishio, T. Mok, G. Scagliotti, D. Cesic, S. Sutradhar, A.T. Shaw

Institutions: Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Seoul National University, Seoul National University Hospital, Sarah Cannon, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Chinese University of Hong Kong, Prince of Wales Hospital, University of Turin, Novartis (United States), Massachusetts General Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Celgene, Vertex Pharmaceuticals, Clovis Oncology, Astellas Pharma, Ipsen, Genentech

OpenAlex ID: W2340678971

FWCI: 3.705

Cites:

Cited by: 19

Related to: 10